Mykronor (Noradrenaline Tartrate)

• Mykronor, a vasopressor acting on the adrenergic system, is indicated for several acute shock states.
• Acute hypotension: restores systemic blood pressure in patients with sudden drops in arterial pressure.
• Septic shock: improves hemodynamic stability during severe infection‑related circulatory failure.
• Cardiogenic shock: supports cardiac output when the heart cannot maintain adequate perfusion.
• Anesthesia‑induced hypotension: counteracts blood pressure reductions caused by anesthetic agents during surgery.

• Noradrenaline tartrate acts as an agonist at α1‑adrenergic receptors, producing peripheral vasoconstriction that raises systemic vascular resistance. It also stimulates β1‑adrenergic receptors modestly, enhancing myocardial contractility and cardiac output. The combined α‑mediated vasoconstriction and β‑mediated inotropic effect increase arterial pressure, making it useful for rapid correction of hypotensive states.

Administration of Mykronor may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Tachycardia: increased heart rate.
• Headache: pressure sensation in the head.
• Nausea: feeling of sickness.
• Peripheral ischemia: reduced blood flow to extremities.
• Anxiety: heightened nervousness or restlessness.

Serious or Rare Side Effects

• Severe hypertension: dangerously high blood pressure.
• Arrhythmias: abnormal heart rhythms including ventricular tachycardia.
• Myocardial ischemia: reduced blood flow to heart muscle.
• Limb necrosis: tissue death due to extreme vasoconstriction.
• Pulmonary edema: fluid accumulation in lungs.

Prior to using Mykronor, clinicians should consider several safety considerations to minimize risk.

• Cardiac disease: monitor for ischemia and arrhythmias.
• Peripheral vascular disease: avoid excessive dosing that may worsen limb perfusion.
• Severe hypertension: titrate carefully to prevent dangerous pressure spikes.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Concomitant MAO inhibitors: discontinue to reduce risk of hypertensive crisis.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mykronor can interact with other agents that affect cardiovascular tone or catecholamine metabolism.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe hypertension.
• Tricyclic antidepressants: additive pressor effects.
• Beta‑blockers: may blunt desired increase in cardiac output.
• Vasopressin: excessive vasoconstriction.
• Calcium channel blockers: unpredictable blood pressure responses.

Moderate Interactions (Monitor Closely)

• General anesthetics: may potentiate hypotensive episodes.
• Diuretics: can alter intravascular volume affecting response.
• ACE inhibitors: may reduce effectiveness of blood pressure support.